The Use of Tiagabine Augmentation for Treatment-Resistant Anxiety Disorders: A Case Series

Thomas L. Schwartz, MD

Psychopharmacology Bulletin 36(2): 53-57, 2002/04/15; https://doi.org/10.64719/pb.4223

Abstract

Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety. Psychopharmacology Bulletin. 2002;36(2):53-57

Keywords

anxiety disorder, anxiolytic, pharmacotherapy, tiagabine, treatment resistance

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00

Add to Cart

How to Cite

Thomas L. Schwartz, MD. The Use of Tiagabine Augmentation for Treatment-Resistant Anxiety Disorders: A Case Series. Psychopharmacology Bulletin. 2002/04/15; 36(2):53-57. https://doi.org/10.64719/pb.4223